ReviewWorld journal of surgical oncology2026
The evolving landscape of colorectal liver metastasis management: from resection to transplantation - a narrative review.
Review in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer remains a leading cause of cancer-related mortality worldwide, with the liver representing the most common site of metastatic spread. The management of colorectal liver metastases (CRLM) has undergone a profound transformation over the past three decades, evolving from a surgical discipline focused solely on resectability to a complex, multimodal enterprise integrating advanced systemic therapies, refined surgical techniques, regional chemotherapy, local ablative procedures, and most recently, liver transplantation for highly selected patients. This narrative review synthesizes contemporary evidence from recent landmark trials and large cohort studies to provide a comprehensive overview of the current treatment landscape. We examine the evolution of surgical resection as the cornerstone of curative-intent therapy, the ongoing debate surrounding perioperative chemotherapy timing and regimens, and the emerging role of thermal ablation as a non-inferior alternative for small metastases. The revival of hepatic arterial infusion pump chemotherapy and the place of targeted therapies are contextualized within modern treatment algorithms. A central focus is the notable introduction of liver transplantation for non-resectable CRLM, with critical appraisal of selection criteria including metabolic tumor volume, the Oslo score, and tumor biology. We conclude by proposing a framework for personalized, biology-driven treatment selection that balances oncologic efficacy with patient quality of life and ethical considerations surrounding organ allocation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.